Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > BioSante Reports Product Highlights and Financial Results

May 12th, 2006

BioSante Reports Product Highlights and Financial Results

Abstract:
"We were pleased to start the year by submitting our new drug application for Bio-E-Gel(R), which we believe, if and when approved, may offer the lowest effective dose of estrogen on the market for the treatment of hot flashes," said Stephen M. Simes, BioSante's president and chief executive officer. "Also in the first quarter, positive data from pre-clinical trials with BioVant(TM), our calcium phosphate nanoparticle technology, demonstrated its effectiveness as an adjuvant for flu vaccines, including bird flu. Looking to the remainder of 2006, we aim to continue our success by initiating Phase III clinical studies of LibiGel(R) in female sexual dysfunction."

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Products

Spectradyne Partners with Particle Technology Labs for Measurement Services December 6th, 2018

Mode-Changing MEMS Accelerometer from STMicroelectronics Combines High Measurement Resolution and Ultra-Low Power for Industrial Applications November 7th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Aculon, Inc. Enters into Strategic Partnership Agreement with Henkel Corporation to Supply Key Mobile Device Manufacturers with NanoProof® PCB Waterproof Technology October 17th, 2018

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project